This company seems to have been delisted
Reason: Liquidation
Last recorded trade on: February 20, 2025
Source: https://globalgenes.org/raredaily/bellerophons-board-agrees-to-liquidate-after-trial-failures-and-layoffs/
Reason: Liquidation
Last recorded trade on: February 20, 2025
Source: https://globalgenes.org/raredaily/bellerophons-board-agrees-to-liquidate-after-trial-failures-and-layoffs/
Bellerophon Therapeutics
BLPH
0,01028 €
Share price
-36.84%
Change (1 day)
-81.34%
Change (1 year)
Categories
Bellerophon Therapeutics (BLPH) - Total liabilities
Total liabilities on the balance sheet as of September 2023 : €1.07 Million
According to Bellerophon Therapeutics 's latest financial reports the company's total liabilities are €1.07 Million. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Bellerophon Therapeutics - Total liabilities on balance sheet (from 2013 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2022-12-31 | €5.03 M | 8.49% |
| 2021-12-31 | €4.64 M | -52.39% |
| 2020-12-31 | €9.74 M | 14.74% |
| 2019-12-31 | €8.49 M | -32.99% |
| 2018-12-31 | €12.67 M | -61.39% |
| 2017-12-31 | €32.84 M | 194.99% |
| 2016-12-31 | €11.13 M | 50.78% |
| 2015-12-31 | €7.38 M | -14.1% |
| 2014-12-31 | €8.59 M | -38.73% |
| 2013-12-31 | €14.02 M | 28.28% |
| 2012-12-31 | €10.93 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Baxter BAX | €12.21 B | 1,134,454.14% | 🇺🇸 USA |
 Abeona Therapeutics
ABEO | €49.67 M | 4,515.29% | 🇺🇸 USA |
 Abbott Laboratories ABT | €27.75 B | 2,578,243.95% | 🇺🇸 USA |
 Lantheus Holdings LNTH | €0.76 B | 70,841.88% | 🇺🇸 USA |